rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer’s disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine

Brain Imaging and Behavior

Volumn 13, Issue 1, 2019, Pages 75-86

  Shirayama, Yukihiko ^a   Takahashi, Michio ^a   Oda, Yasunori ^b   Yoshino, Kouhei ^a,b   Sato, Koichi ^a   Okubo, Toshiyuki ^a   Iyo, Masaomi ^b  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ADAS cog; Alzheimer s disease; Late onset; SPECT

Indexed keywords

DONEPEZIL; GALANTAMINE; IOFETAMINE I 123; CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ANGULAR GYRUS; ANTERIOR CINGULATE; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN PERFUSION; BRAIN REGION; BRAIN TOMOGRAPHY; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL OUTCOME; COGNITION; COGNITIVE DEFECT; COMMAND; COMPREHENSION; CONSTRUCTIONAL PRAXIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ELECTROENCEPHALOGRAM; FEMALE; FOLLOW UP; FRONTAL CORTEX; FUSIFORM GYRUS; HUMAN; IDEATIONAL PRAXIS; IMAGE ANALYSIS; INFERIOR FRONTAL GYRUS; INFERIOR OCCIPITAL GYRUS; INFERIOR PARIETAL LOBULE; INFERIOR TEMPORAL GYRUS; LANGUAGE; LIMBIC CORTEX; LINGUAL GYRUS; LONGITUDINAL STUDY; MALE; MEMORY; MIDDLE FRONTAL GYRUS; MIDDLE OCCIPITAL GYRUS; MIDDLE TEMPORAL GYRUS; OCCIPITAL CORTEX; OCCIPITAL GYRUS; ORAL COMMUNICATION; ORBITAL CORTEX; PARACENTRAL LOBULE; PARAHIPPOCAMPAL GYRUS; PARIETAL CORTEX; PHARMACEUTICAL CARE; POSTCENTRAL GYRUS; POSTERIOR CINGULATE; PRAXIS; PRECUNEUS; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; RECALL; RECTAL GYRUS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; STEREOTACTIC EXTRACTION ESTIMATION METHOD; SUBCALLOSAL GYRUS; SUPERIOR FRONTAL GYRUS; SUPERIOR OCCIPITAL GYRUS; SUPERIOR PARIETAL LOBULE; SUPERIOR TEMPORAL GYRUS; SUPRAMARGINAL GYRUS; TEMPORAL GYRUS; THALAMUS; THREE DIMENSIONAL IMAGING; THREE DIMENSIONAL STEREOTACTIC SURFACE PROJECTION; TRANSVERSE TEMPORAL GYRUS; TREATMENT DURATION; UNCUS; WORD RECOGNITION; BLOOD FLOW; BRAIN; BRAIN CIRCULATION; BRAIN MAPPING; DIAGNOSTIC IMAGING; DRUG EFFECT; METABOLISM; PROCEDURES; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; BRAIN; BRAIN MAPPING; CEREBROVASCULAR CIRCULATION; CHOLINESTERASE INHIBITORS; COGNITIVE DYSFUNCTION; CROSS-SECTIONAL STUDIES; DONEPEZIL; FEMALE; FOLLOW-UP STUDIES; GALANTAMINE; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; REGIONAL BLOOD FLOW; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 85038118353     PISSN: 19317557     EISSN: 19317565     Source Type: Journal    
DOI: 10.1007/s11682-017-9803-y     Document Type: Article

References (50)

1. American Psychiatric Association (1994). Diagnostic and statistic manual of mental disorders (DSN-IV-TR), 4th edn., text rev). Washington DC: American Psychiatric Press.
2. Canu, E., Frisoni, G. B., Agosta, F., Pievani, M., Bonetti, M., & Filippi, M. (2012). Early and late onset Alzheimer’s disease patients have distinct patterns of white matter damage. Neurobiology of Aging, 33, 1023–1033.
3. Cavedo, E., Pievani, M., Boccardi, M., Galluzzi, S., Bocchetta, M., Bonetti, M., et al. (2014). Medial temporal atrophy in early and late-onset Alzheimer’s disease. Neurobiology of Aging, 35, 2004–2012.
4. Ceravolo, R., Volterrani, D., Toqnoni, G., Dell’Aqnello, G., Manca, G., Kiferie, L., et al. (2004). Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clinical Neuropharmacology, 27, 166–170.
5. Chaudhart, S., Scouten, A., Schwindt, G., Janik, R., Lee, W., Sled, J. G., et al. (2013). Hemodynamic effects of cholinesterase inhibition in mild Alzheimer’s disease. Journal of Magnetic Resonance Imaging, 28, 26–35.
6. Desgranges, B., Baron, J. C., Giffard, B., Chételat, G., Lalevée, C., de la Sayette, V., et al. (2002). The neural basis of instruction in free recall and cued recall: a PET study in Alzheimer’s disease. Neuroimage, 17, 1658–1664.
7. Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., et al. (2010). Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurology, 9, 1118–1127.
8. Fletcher, P. C., Frith, C. D., Grasby, P. M., Shallice, T., Frackowiak, R. S., & Dolan, R. J. (1995). Brain systems for encoding and retrieval of auditory-verbal memory. An in vivo study in humans. Brain, 118, 401–416.
9. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-mental state. A practical method for grading the cognitive state of patients for the clinicians. Journal of Psychiatric Research, 12, 189–198.
10. Frisoni, G. B., Pievani, M., Testa, C., Sabattoli, F., Bresciani, L., Bonetti, M., et al. (2007). The topography of grey matter involvement in early and late onset Alzheimer’s disease. Brain, 130, 720–730.
11. Giacobini, E. (2000). Cholinestrase inhibitor therapy stabilize symptoms of Alzheimer disease. Alzheimer Disease and Associated Disorders, 14 suppl 1, S2-S10.
12. Grady, C. L., Haxby, J. V., Horwitz, B., Berg, G., & Rapoport, S. I. (1987). Neuropsychological and cerebral metabolic function in early vs late onset dementia of the Alzheimer type. Neuropsychologia, 25, 807–816.
13. Hachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., et al. (1975). Cerebral blood flow in dementia. Archives of Neurology, 32, 632–637.
14. Hanyu, H., Sato, T., Hirao, K., Kanetaka, H., Iwamoto, T., & Koizumi, K. (2010). The progression of cognitive deterioration and regional cerebral blood flow patterns in Alzheimer’s disease: a longitudinal SPECT study. Journal of Neurological Sciences, 290, 96–101.
15. Hirano, K., Ohnishi, T., Hirata, Y., Yamashita, F., Mori, T., Moriguchi, Y., et al. (2005). The prediction of rapid conversion of Alzheimer’s disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage, 28, 1014–1021.
16. Honda, H., Terada, S., Sato, S., Oshima, E., Ikeda, C., Nagao, S., et al. (2014). Subjective depressive mood and regional blood flow in mild Alzheimer’s disease. International Psychogeriatrics, 26, 817–823.
17. Hongo, J., Nakaaki, S., Shinagawa, Y., Murata, Y., Sato, J., Tatsumi, H., et al. (2008). SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders, 26, 556–566.
18. Ishii, K., Kawachi, T., Sasaki, H., Kono, A. K., Fukuda, T., Kojima, Y.,et al (2005). Voxel-based morphometric comparison between early- and late-onset mild Alzheimer’s disease and assessment of diagnostic performance of Z score images. American Journal of Neuroradiology, 26, 333–340.
19. Johnson, K. A., Jones, K., Holman, B. L., Spiers, P. A., Satllin, A., & Albert, M. S. (1998). Preclinical prediction of Altzheimer’s disease using SPECT. Neurology, 50, 1563–1571.
20. Joubert, S., Gour, N., Guedi, E., Didic, M., Guériot, C., Koric, L., et al. (2016). Early-onset and late-onset Alzheimer’s disease are associated with distinct patterns of memory impaiment. Cortex, 74, 217–232.
21. Kaiser, N. C., Melrose, R. J., Liu, C., Sultzer, D. L., Jimenez, E., Su, M., et al. (2012). Neuropsychological and neuroimaging markers in early versus late-onset Alzheimer’s disease. American Journal of Alzheimer’s Disease and Other Dementias, 27, 520–529.
22. Keller, C., Kadir, A., Forsberg, A., Porras, O., & Noerberg, A. (2011). Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer’s disease patients. Journal of Alzheimer’s Disease, 24, 109–123.
23. Kemp, P. M., Holmes, C., Hoffmann, S. M., Bolt, L., Holmes, R., Rowden, J., et al. (2003). Alzheimer’s disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia. Journal of Neurology, Neurosurgery, and Psychiatry, 74, 715–719.
24. Kimura, N., Kumamoto, T., Masuda, T., Hanaoka, T., Okazaki, T., & Arakawa, R. (2012). Evaluation of the cerebral blood flow changes during long-term donepezil therapy in patients with Alzheimer’s disease using 3DSRT. Journal of Neuroimaging, 22, 299–304.
25. Kogure, D., Matsuda, H., Ohnishi, T., Asada, T., Uno, M., Kunihiro, T., et al. (2000). Longitudinal evaluation of early Alzheimer’s disease using brain perfusion SPECT. Journal of Nuclear Medicine, 41, 1155–1162.
26. Kouneiher, F., Charron, S., & Koechlin, E. (2009). Motivation and cognitive control in the human prefrontal cortex. Nature Neuroscience, 12, 939–945.
27. Kumar, A., Schapiro, M. B., Grady, C., Haxby, J. V., Wagner, E., Salerno, J. A., et al. (1991). High-resolution PET studies in Alzheimer’s disease. Neuropsychopharmacology, 4, 35–46.
28. Kume, K., Hanyu, H., Sato, T., Hirao, K., Shimizu, S., Kanetaka, H., et al. (2011). Vascular risk factors are associated with faster decline of Alzheimer disease: a longitudinal SPECT study. Journal of Neurology, 258, 1295–1303.
29. Lee, D. Y., Choo, I. H., Jhoo, J. H., Kim, K. W., Youn, J. C., Lee, D. S., et al. (2006). Frontal dysfunction underlie depressive syndrome in Alzheimer disease: a FDG-PET study. American Journal of Geriatric Psychiatry, 14, 625–628.
30. Li, W., Antuono, P. G., Xie, C., Chen, G., Jones, J. L., Ward, B. D., et al. (2012). Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer’s disease after 12-week donepezil treatment. Neuroimage, 60, 1083–1091.
31. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology, 34, 939–944.
32. Minoshima, S., Frey, K. A., Koeppe, R. A., Foster, N. L., & Kuhl, D. E. (1995). A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. Journal of Nuclear Medicine, 36, 1238–1248.
33. Mizumura, S., Kumita, S., Cho, K., Ishihara, M., Nakajo, H., Toba, M., et al. (2003). Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation. Annals of Nuclear Medicine, 17, 289–295.
34. Möller, C., Vrenken, H., Jiskoot, L., Versteeg, A., Barkhof, F., Scheltens, P., et al. (2013). Different patterns of gray matter atrophy in early-and late-onset Alzheimer’s disease. Neurobiology of Aging, 34, 2014–2022.
35. Nagahama, Y., Nabatame, H., Okina, T., Yamauchi, H., Narita, M., Fujimoto, N., et al. (2003). Cerebral correlations of the cognitive decline in probable Alzheimer’s disease. European Neurology, 50, 1–9.
36. Nakano, S., Asada, T., Matsuda, H., Uno, M., & Takasaki, M. (2001). Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer’s disease. Journal of Nuclear Medicine, 41, 1441–1445.
37. Nobili, F., Vitali, P., Canfora, M., Girtler, N., De Leo, C., Mariani, G., et al. (2002). Effects of long-term Donepezil therapy on rCBF of Alzheimer’s patients. Clinical Neurophysiology, 113, 1241–1248.
38. Potkin, S. G., Anand, R., Fleming, K., Alva, G., Keator, D., Carreon, D., et al. (2001). Brain metabolic and clinical effects of rivastigmine in Alzheimer’s disease. International Journal of Neuropsychopharmacology, 4, 223–230.
39. Reisberg, B., Ferris, S. H., Anand, R., de Leon, M. J., Schneck, M. K., Buttinger, C., et al. (1984). Functional staging of dementia of the Alzheimer’s type. Annals of the New York Academy of Sciences, 435, 481–483.
40. Roeltgen, D. P., & Heilman, K. M. (1984). Lexical agraphia. Further support for the two-system hypothesis of linguistic agraphia. Brain, 107, 811–827.
41. Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer’s disease. American Journal of Psychiatry, 141, 1356–1364.
42. Rushworth, M. F., Buckley, M. J., Behrens, T. E., Walton, M. E., & Bennerman, D. M. (2007). Functional organization of the medial frontal cortex. Current Opinion of Neurobiology, 17, 220–227.
43. Sá, F., Pinto, P., Cunha, C., Lemos, R., Letra, L., Simões, M., et al. (2012). Differences between early and late-onset Alzheimer’s disease in neuropsychological tests. Frontiers in Neurology, 14, 81.
44. Shimizu, S., Kanetake, H., Hirose, D., Sakurai, H., & Hanyu, H. (2015). Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blod flow changes in patients with Alzheimer’s disease: a 12-month, randomized, and open-label trial. Dementia and Geriatric Cognitive Disorders Extra, 5, 135–146.
45. Stefanova, E., Wall, A., Almkvist, O., Nilsson, A., Forsberg, A., Långström, B., et al. (2006). Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s disease. Journal of Neural Transmission, 113, 205–218.
46. Takahashi, M., Oda, Y., Okubo, T., & Shirayama, Y. (2017). Relationships between cognitive impairment on ADAS-cog and regional cerebral blood flow using SPECT in late-onset Alzheimer’s disease. Journal of Neural Transmission, 124, 1109–1121.
47. Tateno, M., Kobayashi, S., Utsumi, K., Morii, H., & Fujii, K. (2008). Quantitative analysis of the effects of donepezil on regional cerebral blood flow in Alzheimer’s disease by using an automated program, 3DSRT. Neuroradiology, 50, 723–727.
48. Ushijima, Y., Okuyama, C., Mori, S., Kubota, T., Nakai, T., & Nishimura, T. (2006). Regional cerebral blood flow in Alzheimer’s disease: comparison between short and long-term donepezil therapy. Annals of Nuclear Medicine, 20, 425–429.
49. Verma, N., Beretvas, S. N., Pascual, B., Masdeu, J. C., & Markey, M. K. (2015). New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. Alzheimers Research & Therapy, 7, 64.
50. 99 Tc]-d,l-HMPAO SPECT study. Journal of Neurology, Neurosurgery, and Psychiatry, 57, 285–295.